Given the important roles of the PI3K/Akt pathway in CSC formation during the progression of tumor initiation and relapse, developing therapeutic inhibitors against PI3K may be a promising therapeutic strategy to eliminate CSCs in cancer therapy. This evidence concerns the gene AKT1 and neoplasm.